Abstract Body

An emerging paradigm suggests that the gut-associated glycome is critical to the maintenance of a homeostatic relationship between the host and its gut microbiota. In HIV infection, alterations in glycan metabolism may contribute to HIV-mediated intestinal damage, microbial translocation, and chronic inflammation. Given that we recently found that the TLR9 agonist lefitolimod (MGN1703, Mologen AG) increased microbiome diversity in HIV-1 infected individuals at multiple phylogenetic levels in Shannon and Simpson indices (PMID: 28766555), we hypothesized that lefitolimod-mediated changes in the gut glycome promoted changes in microbiome diversity.

Sigmoid biopsies and stool samples were collected (at baseline and after the last dose) from 8 HIV+ adults on suppressive antiretroviral therapy who received lefitolimod (60 mg s.c.) twice weekly for 4 weeks. Ribosomal RNA gene amplicon libraries from fecal samples were sequenced, and all datasets were rarefied to 14,500 reads for calculations of both beta and alpha diversity. Sigmoid tissue was digested and percoll-enriched intestinal mononuclear cells were obtained. The tissue expression of 424 glycosylation-associated genes (glycogenes) was measured using RNA-sequencing. False-discovery rate (FDR) was used to correct for multiple comparisons.

Overall, we found 51 unique gut-associated glycogenes that significantly correlated with 122 microbiome classifications (FDR<0.05). When we filtered the data to only the glycogenes that were significantly modulated by lefitolimod, we identified 10 glycogenes with diverse functions including: mucin-type O-glycosylation synthesis (N-acetyl-galactosaminyltransferases); mannose synthesis and metabolism; and anti-microbial C-type lectin-mediated innate immunity (p<0.05). The changes in these glycogenes correlated strongly (FDR<0.05) with the longitudinal changes in microbiome diversity in multiple taxa including Alphaproteobacteria (Proteobacteria), Paraprevotellaceae (Bacteroidetes) and several species of Firmicutes.

The degree of glycosylation in the gut directly impacts the ability to maintain a functional mucus layer and healthy intestines. Our analyses identified a gut glycomic signature associated with lefitolimod treatment that may influence intestinal homeostasis by modulating alpha diversity of the gut microbiome. Our data highlight that host glycomics is an important tool for evaluating impact of novel HIV interventions, particularly within the context of HIV eradication.